Vishwas Seshadri, Ph.D., M.B.A.

Vishwas Seshadri, Ph.D., M.B.A.

Chief Executive Officer, Director

At Celgene (BMS), Dr. Seshadri served in roles of increasing responsibility focused on research & development and commercialization for novel therapies in hematology and oncology, most recently as Executive Director & Worldwide Brand Leader for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphoma. While at Celgene, he led franchise level marketing and the project management office for CAR T commercialization and led teams supporting the successful global launch of Breyanzi®. He also led development project teams for clinical development and regulatory submissions for REVLIMID® (lenalidomide) in lymphoma, strategic go/no-go decisions for Avadomide and IMFINZI® (durvalumab) while implementing program-wide efficiency measures, and managed post-marketing commitments for ISTODAX® (romidepsin). Previously, he was Head of Early-Stage Upstream Process Development for Biologics at Dr. Reddy's Laboratories, where he led cell-line development, current Good Manufacturing Practices (cGMP) cell banking, characterization, and cell culture optimization for biosimilars. Dr. Seshadri completed his Ph.D. in Microbiology, Immunology & Molecular Biology and his post-doc in epigenetics at University of Arizona, and earned his M.B.A. in Finance and Healthcare from the Wharton School of the University of Pennsylvania.

Edward Carr

Edward Carr

Chief Financial Officer, Principal Financial Officer

Ed Carr, Chief Accounting Officer, joined Abeona in 2018, bringing more than 25 years of corporate public accounting experience to the Company. Most recently, he served as Vice President and Assistant Controller at Coty Inc., a publicly listed multinational company. Mr. Carr has significant experience managing various accounting, financial reporting, internal controls, tax and treasury matters. Prior to Coty, he served for more than 10 years as Chief Accounting Officer at Foster Wheeler AG. Mr. Carr, who is a Certified Public Accountant, began his career at Ernst & Young LLP. He holds a B.S. and Master of Professional Accountancy from West Virginia University.

Greg Gin

Greg Gin

Vice President, Investor Relations and Corporate Communications

Greg Gin joined Abeona as Vice President, Investor Relations in May 2020. In this role, he is responsible for all aspects of Abeona’s investor relations program, along with involvement in wider communications programs and supporting the company’s financing activities. Mr. Gin has served as the Head of Investor Relations at four public companies and brings more than 25 years of investor relations, communications, and capital markets experience with small- and mid-cap biotechnology and specialty pharmaceutical companies developing novel treatments for orphan diseases and areas of high unmet medical need. Immediately prior to joining Abeona, Mr. Gin was Head of Investor Relations at Affimed, an immuno-oncology company, where he was responsible for the company’s global investor relations program.

Brian Kevany, Ph.D.

Brian Kevany, Ph.D.

Vice President, Chief Technical Officer

Brian Kevany, Ph.D., joined Abeona at the beginning of 2018 as a scientist in the product development department bringing 15+ years of molecular biology and biochemistry research training to Abeona. Prior to joining Abeona, he managed a small biotechnology startup company which utilized next-generation sequencing for high throughput genotyping in both the medical and agricultural spaces. A postdoctoral research position at the University of Wisconsin-Madison, working on developing new first-line antibiotics to treat drug-resistant tuberculosis, and a Fellowship at Case Western Reserve University, studying a wide range of vision research topics, resulted in an exemplary publication record in a wide range of peer-reviewed journals. His research at Case Western, under the mentorship of Dr. Krzysztof Palczewski, involved studying both the biochemical basis of retinal development as well as the pathophysiology of animal models of blinding diseases. Prior to his postdoctoral research, he earned a Ph.D. in Molecular and Cellular Biology from the University of Florida and a B.S. degree with honors from Michigan State University.

Kristina Maximenko

Kristina Maximenko

Vice President, Human Resources

Ms. Maximenko has 15 years of human resources experience, having most recently served as the Global HR Director and Head of HR for Advanced Accelerator Applications (AAAP), a Novartis company. Prior to Novartis’ acquisition of AAAP, she was responsible for more than 700 employees operating in a matrix environment within 11 International locations and in more than 20 US states.

Ms. Maximenko has hands-on experience setting up the HR function from the ground up in growing biotechs from pre-clinical to commercialization stage and building out teams in various functional areas including R&D, Medical Affairs, Commercial, Quality & TechOps, and others. She’s got expertise in multiple HR disciplines, including talent acquisition, employee relations, organizational development and compensation.

Ms. Maximenko received a Master of Laws degree in International Law from Far Eastern National University with additional certifications in Human Resources.

Scott Nogi

Scott Nogi

Vice President, Business Operations

Scott Nogi, Vice President of Business Operations, joined Abeona in 2018 with 20 years of operational and administrative management expertise across a wide range of organizations. In his role, he leads Business Development activities and is responsible for information technology (IT), database management systems (DBMS), and commercial property management. Previously, Mr. Nogi held roles as Vice President of Business Development at Access Pharmaceuticals, Inc., where he worked on partnerships for an oral mucoadhesive product in the cancer space; and Vice President of Operations at SCO Capital Management, a biotech-focused value fund, where he managed all operations, audit, fund administration, IT systems, and human resources. Mr. Nogi also served as Executive Director of Kolot Chayeinu / Voices of Our Lives, a non-profit organization, where he led the business strategy and operations, finances, facilities, and staff. Mr. Nogi earned his MBA in Management and Strategy from the Stern School of Business at New York University and his BFA also from New York University.

Brendan O’Malley, J.D., Ph.D.

Brendan O’Malley, J.D., Ph.D.

Senior Vice President, General Counsel

Brendan O’Malley, J.D., Ph.D., joined Abeona in 2019 as Chief IP Counsel, bringing significant technical and legal expertise to the Abeona team.  Prior to joining Abeona, he was a partner at the prominent New York patent litigation firm Fitzpatrick Cella Harper & Scinto, where he started his career as a summer associate in 2006, and then at Venable LLP, which merged with Fitzpatrick in 2018.  While at Fitzpatrick and Venable, Dr. O’Malley litigated a wide variety of biopharmaceutical patent cases in the United States District Courts, at the Federal Circuit, and before the U.S. Patent and Trademark Office, negotiated numerous settlement and license agreements, and provided many patent opinions in connection with M&A due diligence in the biotech space. 

While attending law school at Benjamin N. Cardozo School of Law, Dr. O’Malley served as a judicial intern to Judge William H. Pauley in the U.S. District Court for the Southern District of New York. 

Before law school, he earned a Ph.D. in Molecular Biology & Microbiology from Tufts University School of Medicine, where he studied the role of protein-protein interactions in hepatitis virus assembly, and a B.S. degree magna cum laude from the University of Massachusetts Dartmouth.